Vaccines for the Treatment of Non-Small Cell Lung Cancer: A Renewed Anticancer Strategy

Gridelli, Cesare; Rossi, Antonio; Maione, Paolo; Ferrara, Marianna; Castaldo, Vincenzo; Sacco, Paola Claudia

doi:10.1634/theoncologist.2009-0017

Cited by 40 publications

(36 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A hypothetic explanation for the success of immunotherapy in the adjuvant setting as compared to advanced disease could be the lower tumor tolerance for immune response for smaller volume of tumor cells [58]. Cancer vaccines, including antigen-specific, tumor-cell specific and dendritic-cell-based vaccines, have been developed.…”

Section: Individualized Immunotherapymentioning

confidence: 99%

Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC)

Mascaux

Ekman

Dooms³

et al. 2012

Curr Respir Care Rep

View full text Add to dashboard Cite

Based on meta-analyses and the results of several trials, adjuvant chemotherapy is currently recommended for stage II and stage III non-small cell lung cancer (NSCLC) patients after complete tumor resection, and may be considered for patients with stage IB NSCLC ≥ 4 cm. As individualized therapy becomes integrated into the care of advanced NSCLC, its role in early stage NSCLC and, in particular, in the adjuvant setting, also will become of greater importance. In the adjuvant setting, prognostic and predictive biomarkers might identify which patients have a worse prognosis and, among them, those who could benefit from customized chemotherapy. In the present review, we summarized the available data and ongoing trials testing the role of individualized adjuvant therapy (chemotherapy, targeted therapy and immunotherapy) in NSCLC.

show abstract

Section: Individualized Immunotherapymentioning

confidence: 99%

Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC)

Mascaux

Ekman

Dooms³

et al. 2012

Curr Respir Care Rep

View full text Add to dashboard Cite

show abstract

“…Allogenic vaccines using lung cancer cell lines overcome the logistical concerns of autologous vaccines, but may lack specificity for the host tumor [26]. Whilst cross presentation of tumor antigens on MHC class I is achievable [27,28], this has largely been proven to be inefficient in vivo, and consequently approaches using allogenic cancer cell lines have been disappointing in clinical trials [29,30].…”

Section: Vaccination Strategiesmentioning

confidence: 99%

Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience

2011

View full text Add to dashboard Cite

“…MUC1 is associated with cellular transformation and can confer resistance to genotoxic agents. In preclinical studies, L-BLP25 induced a cellular immune response characterized by T-cell proliferation in response to MUC1 and production of IFN- (reviewed in Gridelli et al, 2009 (Beaudette et al, 2009). …”

Section: Peptide Vaccinesmentioning

confidence: 99%

Harnessing the Immune System to Fight Cancer: The Promise of Genetic Cancer Vaccines

Aurisicchio¹,

Ciliberto²

2011

Current Cancer Treatment - Novel Beyond Conventional Approaches

View full text Add to dashboard Cite

Vaccines for the Treatment of Non-Small Cell Lung Cancer: A Renewed Anticancer Strategy

Abstract: ABSTRACT

Cited by 40 publications

References 59 publications

Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC)

Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC)

Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience

Harnessing the Immune System to Fight Cancer: The Promise of Genetic Cancer Vaccines

Contact Info

Product

Resources

About